CA2020668A1 - Fused or hybrid protein comprising viral antigen and lymphokine - Google Patents
Fused or hybrid protein comprising viral antigen and lymphokineInfo
- Publication number
- CA2020668A1 CA2020668A1 CA002020668A CA2020668A CA2020668A1 CA 2020668 A1 CA2020668 A1 CA 2020668A1 CA 002020668 A CA002020668 A CA 002020668A CA 2020668 A CA2020668 A CA 2020668A CA 2020668 A1 CA2020668 A1 CA 2020668A1
- Authority
- CA
- Canada
- Prior art keywords
- fused
- lymphokine
- fused protein
- hybrid protein
- viral antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 9
- 102000004169 proteins and genes Human genes 0.000 title abstract 8
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 230000003612 virological effect Effects 0.000 title 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Disclosed are (1) a fused protein obtained by combining an antigen used for vaccine and a lymphokine by the application of gene engineering, (2) a recombinant DNA
containing a nucleotide sequence coding for the above fused protein, (3) a transformant bearing the above recombinant DNA, (4) a method for producing the fused protein which comprises cultivating the above transformant, producing and accumulating the above fused protein in a culture, and collecting the fused protein, and (5) a hybrid protein obtained by chemically combining an antigen used for vaccine with a lymphokine. The resulting fused and hybrid proteins have strong immunogenicity.
containing a nucleotide sequence coding for the above fused protein, (3) a transformant bearing the above recombinant DNA, (4) a method for producing the fused protein which comprises cultivating the above transformant, producing and accumulating the above fused protein in a culture, and collecting the fused protein, and (5) a hybrid protein obtained by chemically combining an antigen used for vaccine with a lymphokine. The resulting fused and hybrid proteins have strong immunogenicity.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17603689 | 1989-07-07 | ||
JP176036/1989 | 1989-07-07 | ||
JP5281690 | 1990-03-06 | ||
JP52816/1990 | 1990-03-06 | ||
JP9393890 | 1990-04-11 | ||
JP93938/1990 | 1990-04-11 | ||
JP138180/1990 | 1990-05-30 | ||
JP13818090 | 1990-05-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2020668A1 true CA2020668A1 (en) | 1991-01-08 |
CA2020668C CA2020668C (en) | 2001-10-02 |
Family
ID=27462829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002020668A Expired - Fee Related CA2020668C (en) | 1989-07-07 | 1990-07-06 | Fused or hybrid protein comprising viral antigen and lymphokine |
Country Status (5)
Country | Link |
---|---|
US (2) | US5556946A (en) |
EP (1) | EP0406857B1 (en) |
AT (1) | ATE123065T1 (en) |
CA (1) | CA2020668C (en) |
DE (1) | DE69019609T2 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100064A (en) * | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
EP0406857B1 (en) * | 1989-07-07 | 1995-05-24 | Takeda Chemical Industries, Ltd. | Proteins and production thereof |
US6737521B1 (en) * | 1990-05-11 | 2004-05-18 | The Rockefeller University | Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria |
US5824319A (en) * | 1990-10-04 | 1998-10-20 | Research Corporation Technologies, Inc. | Varicella-zoster virus antigen |
DE69132404T2 (en) * | 1990-10-04 | 2001-02-15 | Res Corp Technologies Inc | VARICELLA ZOSTER VIRUSANTIGEN |
US5935580A (en) * | 1992-04-21 | 1999-08-10 | Institut Pasteur | Recombinant mutants for inducing specific immune responses |
EP1715047A3 (en) * | 1992-04-21 | 2008-08-27 | Institut Pasteur | Recombinant mutants for inducing specific immune responses |
WO1995013089A1 (en) * | 1993-11-10 | 1995-05-18 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Compositions and method for stimulating antibody release by b lymphocytes |
US7094767B2 (en) | 1994-07-22 | 2006-08-22 | Merck & Co., Inc. | Polynucleotide herpes virus vaccine |
IL114576A0 (en) * | 1994-07-22 | 1995-11-27 | Merck & Co Inc | Polynucleotide herpes virus vaccine |
US6080409A (en) | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
EP0803573A1 (en) * | 1996-04-25 | 1997-10-29 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronic expression construct with cytokines for multivalent vaccines |
EP0805207A1 (en) * | 1996-05-02 | 1997-11-05 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronic expression plasmid for tumor rejection |
DE69824039T2 (en) | 1997-12-08 | 2005-08-18 | Lexigen Pharmaceuticals Corp., Lexington | HETERODIMARY FUSION PROTEINS FOR THE USE OF TARGETED IMMUNOTHERAPY AND GENERAL IMMUNE REGION |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
PL343462A1 (en) * | 1998-04-15 | 2001-08-13 | Lexigen Pharm Corp | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
ATE369384T1 (en) * | 1999-05-19 | 2007-08-15 | Emd Lexigen Res Ct Corp | EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS FC FUSION PROTEINS |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
BR0013231A (en) | 1999-08-09 | 2002-07-23 | Lexigen Pharm Corp | Multiple cytokine-antibody complexes |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
EP1228214A2 (en) | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Erythropoietin forms with improved properties |
ES2269366T3 (en) * | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | IMPROVEMENT OF AVERAGE LIFE IN CIRCULATION OF FUSION PROTEINS BASED ON ANTIBODIES. |
DE60129695T2 (en) * | 2000-06-29 | 2008-06-05 | Merck Patent Gmbh | INCREASING IMMUNE RESPONSES MEDIATED BY ANTIBODY CYTOKIN FUSION PROTEINS BY COMBINED TREATMENT WITH MEDICAMENTS FOR INCREASING IMMUNOCYTIC INJECTION |
EP1188446B1 (en) | 2000-09-15 | 2009-08-05 | Institut Pasteur | Proteinaceous vectors for molecule delivery to CD11b expressing cells |
BR0207854A (en) * | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (en) * | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE |
GB0112818D0 (en) * | 2001-05-25 | 2001-07-18 | Lorantis Ltd | Conjugate |
ES2381025T3 (en) | 2001-12-04 | 2012-05-22 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
AU2003228067B2 (en) * | 2002-04-22 | 2008-05-29 | Recopharma Ab | Mucin fusion polypeptide vaccines, compositions and methods of use thereof |
JP4494977B2 (en) * | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Humanized antibody (H14.18) of mouse 14.18 antibody that binds to GD2 and its IL-2 fusion protein |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
CA2551915C (en) | 2003-12-30 | 2015-06-23 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Il-7 fusion proteins |
PT1699821E (en) * | 2003-12-31 | 2012-08-23 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
EP1702069A2 (en) * | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
RU2437893C2 (en) * | 2004-12-09 | 2011-12-27 | Мерк Патент Гмбх | Il-7 versions with low immunising capacity |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
CA2759333A1 (en) * | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
CN111018994A (en) * | 2018-10-10 | 2020-04-17 | 江苏健安生物科技有限公司 | VZV virus subunit fusion antigen |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703004A (en) * | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
EP0158198A1 (en) * | 1984-03-29 | 1985-10-16 | Takeda Chemical Industries, Ltd. | DNA and use thereof |
US4761375A (en) * | 1984-05-08 | 1988-08-02 | Genetics Institute, Inc. | Human interleukin-2 cDNA sequence |
US5109113A (en) * | 1986-05-02 | 1992-04-28 | Genentech, Inc. | Membrane anchor fusion polypeptides |
NZ221298A (en) * | 1986-08-01 | 1990-07-26 | Commw Scient Ind Res Org | A recombinant vaccine comprising an antigenic polypeptide component together with a lymphokine component |
IL84154A0 (en) * | 1986-10-16 | 1988-03-31 | Microgenesys Inc | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same |
ATE136468T1 (en) * | 1986-10-20 | 1996-04-15 | Chiron Corp | VACCINE FOR TREATING HSV |
US5273876A (en) * | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
ZA888978B (en) * | 1987-12-04 | 1990-07-25 | Du Pont | Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension |
EP0369387B1 (en) * | 1988-11-14 | 1996-05-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Spherical vinyl chloride resin granules and process for producing the same |
ZA898139B (en) * | 1988-11-17 | 1990-08-29 | Hoffmann La Roche | Recombinant interleukin-2 hybrid proteins |
IE63847B1 (en) * | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
CA2035868A1 (en) * | 1989-07-06 | 1991-01-07 | Richard C. Svrluga | Hybrid molecules |
EP0406857B1 (en) * | 1989-07-07 | 1995-05-24 | Takeda Chemical Industries, Ltd. | Proteins and production thereof |
DE10021124A1 (en) * | 2000-04-29 | 2001-10-31 | Efen Elektrotech Fab | Capacitative divider comprises a conductor which is constituted at least in parts as a fuse, and serves for connecting the capacitative component with the divider terminals |
JP3664091B2 (en) * | 2001-01-12 | 2005-06-22 | 日本ビクター株式会社 | Modulation method, modulation device, demodulation method, demodulation device, method of recording on information recording medium, information transmission method and information transmission device |
-
1990
- 1990-07-05 EP EP90112851A patent/EP0406857B1/en not_active Expired - Lifetime
- 1990-07-05 AT AT90112851T patent/ATE123065T1/en not_active IP Right Cessation
- 1990-07-05 DE DE69019609T patent/DE69019609T2/en not_active Expired - Fee Related
- 1990-07-06 CA CA002020668A patent/CA2020668C/en not_active Expired - Fee Related
-
1995
- 1995-02-08 US US08/386,354 patent/US5556946A/en not_active Expired - Fee Related
-
1996
- 1996-02-13 US US08/600,545 patent/US5728552A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0406857B1 (en) | 1995-05-24 |
DE69019609D1 (en) | 1995-06-29 |
ATE123065T1 (en) | 1995-06-15 |
US5556946A (en) | 1996-09-17 |
CA2020668C (en) | 2001-10-02 |
EP0406857A1 (en) | 1991-01-09 |
US5728552A (en) | 1998-03-17 |
DE69019609T2 (en) | 1995-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2020668A1 (en) | Fused or hybrid protein comprising viral antigen and lymphokine | |
EP1225225A3 (en) | Osteogenic devices | |
CA2113712A1 (en) | Papilloma virus vaccine | |
ATE70308T1 (en) | HYBRID PARTICLE IMMUNOGENS. | |
AU4545889A (en) | Synthetic dna derived recombinant hiv antigens | |
DE68922917D1 (en) | KEX2 endoprotease and process for its preparation. | |
CA2091181A1 (en) | Cloning of chicken anaemia dna | |
IT1223334B (en) | IMMUNOLOGICALLY ACTIVE POLYPEPTIDES WITH AN ALTERED TOXICITY USEFUL FOR THE PREPARATION OF AN ANTIPERTOX VACCINE | |
IL70776A (en) | Recombinant dna molecule encoding at least one polypeptide displaying the immunogenicity of at least one merozoite antigen or asexual blood stage antigen of p.falciparum,vectors comprising the dna molecule,host cells transformed thereby,immunogenic polypeptides produced by host cells and compositions containing the polypeptides | |
ES555124A0 (en) | PROCEDURE FOR PREPARING PARTICLES THAT CONTAIN AMINO ACID SEQUENCES AND THAT HAVE IMMUNOGENOUS PROPERTIES | |
WO2000006736A3 (en) | Nucleic acids and proteins from group b streptococcus | |
ATE142694T1 (en) | NEW METHOD FOR PRODUCING NON-FUSIONED PROTEIN IN E. COLI | |
AU630861B2 (en) | Recombinant hiv-2 polypeptides | |
HK140095A (en) | Hepatitis surface antigen particle vaccine | |
CA2040810A1 (en) | Process for producing foreign proteins in streptomyces | |
ATE99331T1 (en) | FUSION PROTEINS AND PRODUCTION THEREOF. | |
EP0276778A3 (en) | High level expression in e. coli of soluble mature hil-1beta and derivatives with altered biological activity | |
CA2051010A1 (en) | Human luteinizing hormone-chorionic gonadotropin receptor protein, dna and use thereof | |
DK172990A (en) | A fusion protein, particles which comprise it, a vaccine which comprises such particles, a nucleic acid which encodes the fusion protein, expression vectors which comprise the nucleic acid, cells which comprise the vectors, a process for preparing a peptide, and a diagnostic reagent | |
EP0261534A3 (en) | Improved gene expression in yeast | |
CA2323506A1 (en) | Mammalian blood loss-induced gene, kd312 | |
EP0343132A3 (en) | Methods and systems for producing hiv antigens | |
SU1380209A1 (en) | RECOMBINANT PLASMID DNA PUR 291-HAV 22 ENCODING SYNTHESIS OF HYBRID POLYPEPTIDE OF HEPATITIS VIRUS A ANTIGENIC DETERMINANTS WITH β-GALACTOSIDASE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |